Skip to main content

Table 2 Baseline demographics and clinical characteristics by country

From: The real-world effectiveness of sucroferric oxyhydroxide in European hemodialysis patients: a 1-year retrospective database analysis

Parametera

France (n = 174)

Italy (n = 106)

Portugal (n = 147)

Russia (n = 73)

Spain (n = 596)

Overall cohort (N = 1096)

Sex, n (%)

 Male

106 (60.9)

69 (65.1)

101 (68.7)

39 (53.4)

406 (68.1)

721 (65.8)

 Female

68 (39.1)

37 (34.9)

46 (31.3)

34 (46.6)

190 (31.9)

375 (34.2)

Age, years

62.5 ± 15.4

60.5 ± 14.9

55.3 ± 13.3

54.8 ± 14.7

62.1 ± 14.5

60.6 ± 14.8

Body mass index, kg/m2

27.6 ± 6.9

27.5 ± 6.1

26.6 ± 6.0

27.3 ± 5.4

28.1 ± 5.9

27.8 ± 6.0

Dialysis vintage, months

44.2 ± 59.5

71.3 ± 74.1

72.0 ± 68.5

57.3 ± 46.7

61.1 ± 74.4

61.0 ± 70.0

Comorbidities, n (%)

 Diabetes

42 (24.1)

26 (24.5)

29 (19.7)

23 (31.5)

199 (33.4)

319 (29.1)

 Congestive heart failure

14 (8.1)

20 (18.9)

14 (9.5)

36 (49.3)

190 (31.9)

274 (25.0)

  1. aContinuous variables are presented as mean ± standard deviation unless otherwise specified